Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension
- Lauren Brash, MD
- Gareth D. Barnes, MD
- Melanie J. Brewis, MD
- A. Colin Church, MD
- Simon J. Gibbs, MD
- Luke S.G.E. Howard, MD
- Geeshath Jayasekera, MBChB
- Martin K. Johnson, MD
- Neil McGlinchey, MBChB
- Joelle Onorato, PhD
- Joanne Simpson, MD
- Colin Stirrat, MD
- Stephen Thomson, MBChB
- Geoffrey Watson, MD
- Martin R. Wilkins, MD
- Carrie Xu, MS
- David J. Welsh, PhD
- David E. Newby, MD
- Andrew J. Peacock, MD
DOIAbstract
Summary: Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for ...
Add to ORKG